Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
130 EUR | 0.00% | +0.78% | -1.22% |
04-26 | REDCARE PHARMACY : Deutsche Bank reiterates its Buy rating | ZD |
04-26 | REDCARE PHARMACY : Hauck & Aufhauser keeps its Buy rating | ZD |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- Over the past four months, analysts' average price target has been revised upwards significantly.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- The company appears highly valued given the size of its balance sheet.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Drug Retailers
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-1.22% | 2.8B | B | ||
-32.21% | 15.27B | B- | ||
-31.97% | 10.84B | B | ||
-30.42% | 6.06B | B | ||
+8.14% | 6.04B | C | ||
-11.41% | 5.86B | C+ | ||
-1.17% | 4.71B | D- | ||
+52.19% | 4.29B | - | C | |
-14.86% | 3.33B | C- | ||
-6.93% | 3.01B | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- RDC Stock
- Ratings Redcare Pharmacy NV